Health Tech — sector dashboard · fobi

Sign in Sign up free

Funding & analysis

Company

00

01

02

03

04

05

06

07

08

09

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

Total Raised

Round sizes
Mega-rounds ($200M+) dominate the past 12 months: Whoop Series G ($575M), Oura Series E ($900M), Verily Growth ($300M), Abridge Series E ($300M), Innovaccer Series F ($275M), and Commure Growth ($200M). Seed and Series A have nearly vanished. Median round size has shifted decisively upward, with late-stage firms capturing 75% of recent capital.
Stage mix
Capital is heavily concentrated in Series D through Growth rounds. Of the past 12 months' 24 dated rounds, 15 are Series D or later, three are Series C, two are Series B, and one is Growth-stage. Seed funding is absent. Early-stage operators are effectively shut out; growth and late-stage dominate.
Lead investors
Fidelity Management & Research Company leads two mega-rounds (Oura $900M, $200M). General Catalyst, Andreessen Horowitz, and TCV each anchored multiple Series D–E rounds. New entrant Goldman Sachs Alternatives led Aidoc Series E. Longtime players Kleiner Perkins and Greylock have gone quiet in 2025–2026 funding activity.